LeMaitre Vascular (LMAT) details insider stock and dividend rights moves

Rhea-AI Filing Summary

LeMaitre Vascular reported insider equity transactions by its Senior Vice President, Operations on a Form 4. On 12/06/2025, 2 shares of common stock were acquired at $0 per share upon the release of dividend equivalent rights, bringing direct holdings before tax withholding to 3,712 shares. Also on that date, 69 shares were disposed of at $84.53 per share as shares withheld by the issuer to satisfy tax withholding obligations from previously awarded restricted stock units, resulting in 3,643 common shares owned directly.

The report also shows several acquisitions of dividend equivalent rights on 12/04/2025 that accrued on restricted stock unit and performance share unit awards originally granted on 12/11/2021, 12/12/2022, 12/8/2023, and 12/6/2024. Each dividend equivalent right is stated to be the economic equivalent of one share of LeMaitre Vascular common stock and to vest proportionately with the related awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kamke Trent G

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR , INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior V. P., Operations

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/06/2025		M		2(1)	A	$0(1)	3,712	D
Common Stock	12/06/2025		F		69(2)	D	$84.53	3,643	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(3)	12/04/2025		A		0.7006		(3)	(3)	Common Stock	0.7006	$0	14.3155	D
Dividend Equivalent Rights	(4)	12/04/2025		A		1.4256		(4)	(4)	Common Stock	1.4256	$0	16.734	D
Dividend Equivalent Rights	(5)	12/04/2025		A		1.4256		(5)	(5)	Common Stock	1.4256	$0	16.7256	D
Dividend Equivalent Rights	(6)	12/04/2025		A		1.8282		(6)	(6)	Common Stock	1.8282	$0	13.2763	D
Dividend Equivalent Rights	(7)	12/04/2025		A		2.1914		(7)	(7)	Common Stock	2.1914	$0	14.7096	D
Dividend Equivalent Rights	(8)	12/04/2025		A		2.1784		(8)	(8)	Common Stock	2.1784	$0	8.5993	D
Dividend Equivalent Rights	(9)	12/06/2025		M			2(9)	(9)	(9)	Common Stock	2	$0	6.5993	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/6/2024. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a performance share unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

7. These dividend equivalent rights accrued on a performance share unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

8. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

9. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/6/2024. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did LeMaitre Vascular (LMAT) disclose in this Form 4?

The filing shows that on 12/06/2025 a company officer acquired 2 shares of LeMaitre Vascular common stock at $0 per share upon the release of dividend equivalent rights, and that 69 shares were disposed of at $84.53 per share as shares withheld by the issuer to cover tax withholding obligations on vested restricted stock units.

How many LeMaitre Vascular (LMAT) shares does the reporting officer own after the transactions?

After the reported transactions on 12/06/2025, the officer directly owns 3,643 shares of LeMaitre Vascular common stock, as shown in the Form 4.

Why were 69 LMAT shares disposed of by the issuer?

The 69 shares reported as disposed of represent shares withheld by LeMaitre Vascular to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/6/2024. The filing states that this transaction is considered an exempt sale pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934.

What are dividend equivalent rights in the LeMaitre Vascular (LMAT) filing?

The document explains that the dividend equivalent rights accrued on various restricted stock unit and performance share unit awards and vest proportionately with those awards. It states that each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock.

Which prior equity awards generated the dividend equivalent rights for LMAT?

The dividend equivalent rights reported on 12/04/2025 accrued on equity awards originally granted on 12/11/2021, 12/12/2022, 12/8/2023, and 12/6/2024, including both restricted stock unit awards and performance share unit awards.

Does this Form 4 involve a 10% owner or an officer of LeMaitre Vascular (LMAT)?

The Form 4 identifies the reporting person as an officer of LeMaitre Vascular, serving as Senior V. P., Operations. The 10% owner box is not indicated; the relationship checked is officer.